The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis hyperalgesia allodynia inflammatory hyperalgesia neuropathic hyperalgesia acute nociception osteoporosis multiple sclerosis-associated spasticity autoimmune disorders allergic reactions CNS inflammation atherosclerosis undesired immune cell activity and inflammation age-related macular degeneration cough leukemia lymphoma CNS tumors prostate cancer Alzheimers disease stroke-induced damage dementia amyotrophic lateral sclerosis, and Parkinsons disease.
